Screener / Orphan Drug Development / PTC Therapeutics
PTCT · NASDAQ
PTC Therapeutics
Compliant
Under AAOIFI Standard 21, PTC Therapeutics is compliant. Its core business is permissible and its interest-bearing debt is below 30% of market cap.
TickerPTCT
ExchangeNASDAQ
SectorOrphan Drug Development
Full ratios for PTC Therapeutics (impure revenue, debt and interest-bearing deposits under all four standards) are being added. Until then this page shows the screening verdict only. See the methodology for how each test works. Purindex publishes this screening to help people understand what they own. It does not recommend buying, selling or holding PTC Therapeutics or any other security.